AngioDynamics (NASDAQ:ANGO) CEO Buys $111,500.00 in Stock

Key Points

• CEO James Clemmer of AngioDynamics purchased 10,000 shares at $11.15 each, totaling $111,500, increasing his ownership to 882,529 shares.
• AngioDynamics reported a revenue increase of 12.1% year-over-year, with quarterly earnings surpassing analyst expectations by posting an EPS of ($0.10).
• Analysts have mixed ratings on AngioDynamics, with price targets ranging from $16.00 to $24.00, while the current consensus target price is $19.33.

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) CEO James Clemmer purchased 10,000 shares of the stock in a transaction dated Thursday, October 9th. The shares were acquired at an average cost of $11.15 per share, with a total value of $111,500.00. Following the acquisition, the chief executive officer directly owned 882,529 shares in the company, valued at $9,840,198.35. This represents a 1.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

AngioDynamics Stock Performance

Shares of AngioDynamics stock traded up $0.02 during trading on Thursday, reaching $11.14. 333,817 shares of the company's stock were exchanged, compared to its average volume of 589,068. AngioDynamics, Inc. has a 1-year low of $5.99 and a 1-year high of $13.50. The company has a market cap of $458.97 million, a P/E ratio of -14.28 and a beta of 0.78. The firm's 50-day moving average price is $10.11 and its 200 day moving average price is $9.79.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company had revenue of $75.71 million during the quarter, compared to analysts' expectations of $72.69 million. During the same quarter in the previous year, the firm earned ($0.11) EPS. AngioDynamics's revenue was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. As a group, equities research analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Institutional Investors Weigh In On AngioDynamics

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming bought a new stake in shares of AngioDynamics during the 2nd quarter valued at about $31,000. Tower Research Capital LLC TRC boosted its position in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock valued at $54,000 after purchasing an additional 4,268 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of AngioDynamics during the 2nd quarter valued at about $90,000. Cerity Partners LLC boosted its position in shares of AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock valued at $121,000 after purchasing an additional 2,333 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of AngioDynamics by 279.5% during the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier's stock valued at $123,000 after purchasing an additional 9,098 shares in the last quarter. Institutional investors own 89.43% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ANGO. Wall Street Zen lowered AngioDynamics from a "buy" rating to a "hold" rating in a research report on Saturday, October 4th. Canaccord Genuity Group boosted their price objective on AngioDynamics from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, October 3rd. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday, July 16th. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research report on Wednesday. Finally, Lake Street Capital began coverage on AngioDynamics in a research report on Wednesday, July 16th. They set a "buy" rating and a $24.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $19.33.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.